This story is developing. The reporting was first published by AstraZeneca US; we are showing everything that is available to us here.
Business
Business
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Reported by AstraZeneca US. Read more of their coverage at the original source.